🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

A Global Challenge

The sexually transmitted infection are on the rise globally, with data suggesting more than 82 million instances per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This approval signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Results and Global Access

As per findings published in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines an injection and a pill. The trial included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to license and sell the drug in many developing nations.

Doctors directly involved have shared positive views. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.